Skip to Content
  • The Soon-Shiong Hype Machine

    I have long been suspicious of people who use the word “moonshot” in the context of biomedical research. It’s lazy shorthand for “WeR… Read More
  • Be Sure The Funds Are Deposited

    I’ve written before here about the many people who are convinced that most (or all) diseases have to do with the body’s pH – most often, you h… Read More
  • What Passes For Positive Data

    So can someone explain this one for me? Halozyme has a hyaluoronidase enzyme (PEGPH20) that they’re developing as a therapeutic agent. The idea is that it… Read More
  • More Juno CAR-T Deaths

    Remember back in the summer when Juno Therapeutics disclosed three patient deaths in one of their CAR-T oncology trials and the trial was put on hold? And then… Read More
  • More Than Was Asked For

    Via AndyBiotech on Twitter, here’s an interesting report from the New England Journal of Medicine. It describes a patient diagnosed with follicular lympho… Read More
  • The Limits of Big Data

    I fear that mentioning the phrase “Big Data” in the first sentence of a blog post will make half the potential readers suddenly remember that they h… Read More
  • Keytruda vs. Opdivo: No Contest

    You don’t always get to see a head-to-head showdown like this one: Merck’s Keytruda (pembrolizumab) and Bristol Myers-Squibb’s Opdivo (nivolum… Read More
Page 1 of 3512345...102030...Last »